Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | HTR5A | P47898 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 4/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152834 | 0.83 | BCHE (0.39) | BCHEPGRKIF11MEN1KMT2A | |
| SCHEMBL24041152 | 0.79 | CDK4 (0.32) | PGRKIF11MEN1KMT2ACDK4 | |
| SCHEMBL21151651 | 0.79 | TDO2 (0.36) | HTR2BHTR5ATDO2BCHENQO2 | |
| SCHEMBL23518252 | 0.77 | PDK2 (0.42) | MEN1KMT2A | |
| SCHEMBL17714932 | 0.76 | KIF11 (0.36) | PGRKIF11MEN1KMT2ACDK4 | |
| SCHEMBL23518358 | 0.76 | PDK2 (0.41) | MEN1KMT2A | |
| SCHEMBL23518239 | 0.74 | PDK2 (0.38) | MEN1KMT2A | |
| SCHEMBL18878282 | 0.74 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL18878316 | 0.74 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL17151655 | 0.74 | MEN1 (0.37) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10580996-B2 | Polycyclic compound and organic light-emitting element comprising same | LG CHEM, LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20180138421-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-17 | — | — | US | disclosed |
| US-20180138421-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180138421-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY2, NR2E3, CRY1 | HTR2B 2847/4885HTR5A 3915/4885TDO2 1287/4885 |
| US-10580996-B2 | Polycyclic compound and organic light-emitting element comprising same | CRY2, NR2E3, CRY1 | HTR2B 2847/4885HTR5A 3915/4885TDO2 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.